DUPIXENT IS THE FIRST BIOLOGIC APPROVED IN CRSwNP THAT TARGETS THE INFLAMMATION UNDERLYING THE DISEASE—SO YOUR PATIENTS CAN ACHIEVE AND MAINTAIN CONTROL
(sense of smell)2,a
aAt Week 52 (SINUS‑52: other secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) (9.53 from a baseline score of 13.46) vs 6% worsening with placebo + INCS (n=153) (-0.77 from a baseline score of 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10]). Analysis of this endpoint was not multiplicity controlled; results are descriptive.3,4
bAt Week 24 (SINUS‑24: coprimary endpoint) with DUPIXENT Q2W + INCS (n=143) (-1.34 from a baseline score of 2.26) vs 18% improvement with placebo + INCS (n=133) (-0.45 from a baseline score of 2.45) (LSM difference: -0.89 [95% CI: -1.07, -0.71]).1
cIndividually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.
INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; SCS, systemic corticosteroid; UPSIT, University of Pennsylvania Smell Identification Test.
Unique Mechanism of Action (MOA)
DUPIXENT is a dual inhibitor of
Multiple Administration Options
Work with your patients to decide how to administer DUPIXENT: either administer at home or administer in the office.1See Dosing and Administration
A patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.
View safety data across clinical trials.
available for patients
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in Your Area
See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.